Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quercus salicina extract, often referred to by the brand names **Ucalon** or **Urocalun**, is a botanical pharmaceutical preparation developed by Japan New Drug Co., Ltd. (Nippon Shinyaku). Derived from the leaves of the *Quercus salicina* (Urajirogashi) tree, it is specifically indicated for the promotion of the discharge of kidney and ureteral stones (urolithiasis). The extract is believed to exert its therapeutic effects through a multifaceted mechanism that includes inhibiting the formation, growth, and aggregation of calcium oxalate crystals, which are the primary components of most urinary calculi. Additionally, it possesses anti-inflammatory and spasmolytic properties that help reduce edema in the urinary tract and relax the smooth muscles of the ureter, thereby facilitating the spontaneous passage of stones. It is widely utilized in East Asian markets, particularly Japan and China, as a conservative management option for patients with small urinary stones.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on quercus salicina extract.